Index

A
ABCA1, knockout mouse, 284
ABCA7, late-onset Alzheimer disease role, 254
ACC-001, amyloid-β immunotherapy, 445
ACE. See Angiotensin-converting enzyme
Acetylcholine receptor
amyloid-β interactions, 195, 320
muscarinic agonist therapy, 485
nicotinic agonist therapy, 485
Acetylcholinesterase, inhibitor therapy, 476–480, 489
Acylpeptide hydrolase (APH), amyloid-β degradation, 396
AD8, Alzheimer disease screening, 13–14
ADAMs
ADAM10 and late-onset Alzheimer disease role, 255–256
amyloid precursor protein processing, 210–211
Aging
Alzheimer disease risks, 15
Alzheimer neuropathology in normal aging, 55–56
healthy cognitive aging, 10–11
Agitation Inventory, 14
α-Secretase. See also ADAMS
amyloid precursor protein processing, 210–211
subcellular sites of processing, 216
AlzGene, late-onset Alzheimer disease variants, 253
AMPA receptor, therapeutic targeting, 486
Amyloid-β
aggregation
biophysics, 434–435
inhibitors
animal studies, 436–437
clinical studies, 437–438
in vitro studies, 435–436
prospects for study, 438
amyloid hypothesis of Alzheimer disease, 405–407
apolipoprotein E interactions, 282–284
receptors
metabolism regulation, 290–291
synaptic suppression antagonism, 287–288
balance between production and clearance, 389–391
BAPTs versus TAUs, 5–6
biochemistry in deposits and plaques, 182–185
cerebrospinal fluid biomarker studies isoforms, 92–95, 97, 100
oligomers, 97
soluble protein, 97
cognitive function disruption, 325, 327–328
diffusible oligomers
molecular dynamics, 188
natural oligomers, 188–190
overview, 186–187
recombinant oligomers, 188
synthetic AB as substrate for oligomer formation, 187–188
fibril structure and properties, 185–186
forms in neuronal impairment, 318–319
history of study, 181–182
immunization therapy
active immunization
ACC-001, 445
AN1792 clinical trial, 441–443
CAD-106, 445
mechanism of action, 439–441, 464
overview, 438
preclinical observations, 439
passive immunization, 443–445
membrane interactions
electrostatic/charge effects, 194
hydrophobic interactions, 194
lipoprotein interactions, 194–195
phase/interface effects, 193–194
receptor interactions, 195
metal ion interactions, 191–193
plasma biomarkers, 102
positron emission tomography imaging
applications, 78–80
limitations, 80
principles, 77–78
production, 212
proteolytic degradation
environmental insults, 392
inhibitors, 398–399
irreversibility, 392
protease defining of amyloid-β pools, 391–392
protease types
acylpeptide hydrolase, 396
angiotensin-converting enzyme, 395
BACE1, 397
BACE2, 397–398
catalytic antibodies, 398
Amyloid-β (Continued)
cathepsin B, 397
cathepsin D, 397
endothelin-converting enzymes, 394
insulin-degrading enzyme, 395–396
matrix metalloproteinases, 395
myelin basic protein, 396
neprilysin, 393–394
neprilysin-like peptidases, 394
overview, 392–393
plasmin, 396
proteasome, 398
regulation of amyloid-β levels, 388–389
sites, 392
therapeutic targeting, 399
synaptic function
early perturbations, 319
extracellular versus intraneuronal amyloid-β effects, 324–325
oligomer receptors in perturbation, 322
synaptic depression enhancement, 321–322
synaptic transmission modulation, 319–321
therapeutic implications, 328–330
transgenic mouse models, 304
Amyloid plaque
clinicopathological correlations, 51
composition, 48
definition, 44
morphology, 49
topographical distribution, 49–50
Amyloid precursor-like proteins (APLPs), γ-secretase processing, 264
Amyloid precursor protein (APP)
amyloid-β production, 212
apolipoprotein E receptor regulation of trafficking and processing, 289–290
apoptosis studies, 236
axonal transport, 233–234
cell and synaptic adhesion studies, 234
gene duplication, 373
gene family, 232
intracellular signaling, 236
isoforms
axon pruning and degeneration, 235
knockout studies, 239
loss of function studies Caenorhabditis elegans, 236–237
Drosophila, 236–237
knockout mice
combined knockouts, 238
conditional knockouts, 239–240
single knockout, 237–238
proteases
BACE1, 207–208
α-secretase, 210–211
γ-secretase and presenilins, 208–210
proteolytic processing
activity-dependent processing, 219–222
degradation, 219
overview, 205–206, 232
subcellular sites of processing, 216, 218
structure, 232–233
subcellular localization, 233
tissue distribution, 233
trafficking
dendritic sorting, 211–212
neurons, 215–217
polarized trafficking
secretase sorting, 213, 215
sorting mechanisms, 212–214
trophic function, 234–235
variants in Alzheimer disease
eyear-onset familial Alzheimer disease, 251
overview, 123, 207
AN1792, clinical trial, 441–443
Angiotensin-converting enzyme (ACE), amyloid-β degradation, 395
Animal models, Alzheimer disease
clinical translation concerns, 309–312
knockout mice, 307–309
transgenic mice, 303–307
APH. See Acylpeptide hydrolase
APLPs. See Amyloid precursor-like proteins
APOE ε4
Alzheimer disease risks, 15, 124, 281
positron emission tomography brain metabolism findings in Alzheimer disease, 76
Apolipoprotein E
amyloid-β interactions, 194–195, 282–284
late-onset Alzheimer disease variants, 252–253, 281–282
neurobiology, 281
receptors. See also specific receptors
amyloid-β-induced synaptic suppression antagonism, 287–288
amyloid-β metabolism regulation, 290–291
amyloid precursor protein trafficking and processing regulation, 289–290
LDLR1 functional overview, 291–293
LRP1 functional overview, 291–293
neuroprotection studies, 288–289
signaling, 285–286
synaptic plasticity studies, 284–287
Tau phosphorylation regulation, 286
types, 280–281
Apoptosis, amyloid precursor protein studies, 236
APP. See Amyloid precursor protein
Arachidonic acid, inflammation mediations, 345
Astrocyte
Alzheimer disease effects, 52
inflammation mediation, 339–340
Attention, Alzheimer disease deficits, 28
ATXN1, late-onset Alzheimer disease role, 253–254
Autophagic vacuole (AV), accumulation in neurons, 373
AV. See Autophagic vacuole
Axona (Ketasyn), Alzheimer disease treatment studies, 484–485, 488

B

BACE1
amyloid-β degradation, 397
amyloid precursor protein processing, 207–208, 423–426
cerebrospinal fluid biomarker studies, 97
inhibitors, 431–433
knockout mouse, 308
polarized sorting, 213, 215
structure, 426, 432
subcellular sites of processing, 216, 218

BACE2
amyloid-β degradation, 397–398
inhibitors, 431–433
BBB. See Blood–brain barrier
Begacestat, presenelin inhibition, 270–271
Behavioral variant frontotemporal dementia. See Frontotemporal lobar degeneration
β-Secretase. See BACE1
BIN1. See Bridging integrator 1
Biomarkers. See Cerebrospinal fluid; Plasma biomarkers
Blood–brain barrier (BBB), dysfunction in Alzheimer disease
GLUT1, 409
LRP, 410–413
overview, 409
RAGE, 410
vascular-specific gene expression, 413–414
BMS-708163, presenelin inhibition, 270–271, 430–431
Body weight, Alzheimer disease risk factor, 119
Bridging integrator 1 (BIN1), variants in Alzheimer disease, 123

C

C9orf72, frontotemporal lobar degeneration mutations, 169–170
CAA. See Cerebral amyloid angiopathy
CAD-106, amyloid-β immunotherapy, 445
Cambridge Mental Disorders of the Elderly Examination, 14
Carbamazepine, agitation management in Alzheimer disease, 481
Cathepsin B, amyloid-β degradation, 397
Cathepsin D, amyloid-β degradation, 397
CBE. See Cerebral blood flow
CBS. See Corticobasal syndrome
CD2AP, late-onset Alzheimer disease role, 254
CD33, late-onset Alzheimer disease role, 253–254
CDK5, inhibitor therapy, 461
CDR. See Clinical Dementia Rating
CERAD Behavior Rating Scale for Dementia, 14
Cerebral amyloid angiopathy (CAA)
apolipoprotein E knockout mice, 283
clinicopathological correlations, 51–52
composition, 51
definition, 44
microvascular degeneration, 409
morphology, 51
topographical distribution, 51
Cerebral blood flow (CBF), Alzheimer disease findings, 408–409
Cerebrolysin, Alzheimer disease treatment studies, 483, 487
Cerebrospinal fluid (CSF), biomarkers for Alzheimer disease
amyloid-β isoforms, 92–95, 97, 100
oligomers, 97
soluble protein, 97
BACE1, 97
clinical trial application
diagnosis/enrichment of Alzheimer disease cases, 103
drug response monitoring, 105–106
safety monitoring, 104–105
stratification of Alzheimer disease cases, 103–104
combination studies, 94, 106–107
diagnostic performance
Alzheimer disease with dementia, 94–95
autopsy-verified Alzheimer disease, 95
preclinical Alzheimer disease, 95–96
prodromal Alzheimer disease, 95
endophenotypes in genetic studies, 106
GAP-43, 100
inflammation and oxidative stress markers, 100–101
neurofilament proteins, 100
overview, 92–93, 98–99
prospects, 106–107
Stable Isotope Labeling Kinetics, 101–102
Tau
phosphorylation, 93–94
total protein, 92–93
visinin-like protein-1, 100
CHMP2B, frontotemporal lobar degeneration mutations, 171
Clinical Dementia Rating (CDR), 14
Clock Drawing test, 14
Clusterin
late-onset Alzheimer disease role, 254
variants in Alzheimer disease, 123
Cognitive enhancement, Alzheimer disease protection, 122–123
Cognitive reserve, Alzheimer disease protection, 120–121
Complement, inflammation mediation, 341–343
Complement receptor 1 (CR1), variants in Alzheimer disease, 123, 254
Copper, amyloid-β interactions, 192–193
Corticobasal syndrome (CBS)
  clinical presentation, 162
  histopathology, 163, 165
COX. See Cyclooxygenase
CR1. See Complement receptor 1
CSF. See Cerebrospinal fluid
Curcumin, Alzheimer disease treatment studies, 490
CX-1837, Alzheimer disease treatment studies, 486
Cyclooxygenase (COX)
  inflammation mediation, 345
  therapeutic targeting in Alzheimer disease, 347–348, 428, 487, 490
D
Definite Alzheimer disease, diagnostic criteria, 11–12, 54
Dementia
  definition, 11
  detection, 11, 13–14
Dementia with Lewy bodies (DLB)
  Alzheimer disease differential diagnosis, 18, 30–31
  Lewy body ubiquitination, 363–364
  overlap with Alzheimer disease, 56–57
Dense-core plaque, definition, 44
Depression
  Alzheimer disease differential diagnosis, 19
  antidepressants in Alzheimer disease, 481
Diabetes type II, Alzheimer disease risk factor, 119
Diffuse plaque, definition, 44
Donezepil (Latrepirdine), Alzheimer disease treatment studies, 487, 489
DLB. See Dementia with Lewy bodies
Docosahexaenoic acid (DHA), Alzheimer disease treatment studies, 483, 487
Donepezil, acetylcholinesterase inhibition, 476, 478–479
Down syndrome, 327
E
E2012, presenelin inhibition, 430
Early-onset familial Alzheimer disease (EO-FAD), 431
ECEs. See Endothelin-converting enzymes
Economic impact, Alzheimer disease, 9
EHT0202. See Etazolate
ELND006, presenelin inhibition, 431
Endothelin-converting enzymes (ECEs), amyloid-β degradation, 394
EO-FAD. See Early-onset familial Alzheimer disease
EPHA1, late-onset Alzheimer disease role, 254
Epidemiology, Alzheimer disease
  definitions and criteria, 115–116
  genetic epidemiology
    common variants, 124
    late-onset Alzheimer disease, 124
    rare variants, 123–124
    incidence, 9, 116–117
  inflammation, 346–347t
    prevalence, 9, 116–117
  protective factors
    cognitive enhancement, 122–123
    cognitive reserve, 120–121
    diet, 121–122
    exercise, 122
  risk factors
    body weight, 119
    cerebrovascular disease, 118
    diabetes type II, 119
    hypertension, 118–119
    smoking, 119–120
    traumatic brain injury, 120
  risk stratification and treatment, 500
Episodic memory, Alzheimer disease deficits, 26–27
Epothilone D, microtubule stabilization in Alzheimer disease, 460
ERT. See Estrogen replacement therapy
Estrogen replacement therapy (ERT), Alzheimer disease treatment studies, 487, 490
Etazolate (EHT0202), Alzheimer disease treatment studies, 486
Executive function, Alzheimer disease deficits, 28–29
Exercise, Alzheimer disease protection, 122
F
Fluorodeoxyglucose. See Positron emission tomography
Flurbiprofen, presenelin inhibition, 428–429
fMRI. See Functional magnetic resonance imaging
Folic acid, Alzheimer disease treatment studies, 484
Frontotemporal dementia and Parkinsonism linked to chromosome 17 (FTDP-17)
  clinical presentation, 163
  histopathology, 166
  Tau mutations, 457
Frontotemporal lobar degeneration (FTLD)
Alzheimer disease
  differential diagnosis, 18–19, 31–32
  overlap, 171–173
  behavioral variant and Alzheimer disease differential diagnosis, 32–33, 35
  clinical presentation
    behavioral variant, 161
    corticobasal syndrome, 162
    logopenic progressive aphasia, 162

© 2011 by Cold Spring Harbor Laboratory Press
motor neuron disease, 163
progressive nonfluent aphasia, 161–162
progressive supranuclear palsy, 162–163
semantic dementia, 161
gene mutations
C9ORF72, 169–170
CHMP2B, 171
FUS, 170
MAPT, 164, 169
TARDBP, 170
VCP, 170–171
histopathology
FTLD-FUS, 168
FTLD-Tau, 163–167
FTLD-TDP, 167–168
FTLD-UPS, 168
history of study, 159–161
FTDP-17. See Frontotemporal dementia and
Parkinsonism linked to chromosome 17
FTLD. See Frontotemporal lobar degeneration
Functional magnetic resonance imaging (fMRI)
Alzheimer disease studies, 72–74
principles, 72
FUS
frontotemporal lobar degeneration mutations, 170
FTLD-FUS, 168
Fyn, Tau interactions, 148

G
Galantamine, acetylcholinesterase inhibition, 479
γ-Secretase. See also Nicastrin; PEN2; Presenelins
amyloid precursor protein processing, 208–210, 423–426
inhibitors, 269–271, 426–431
membrane topology, 262
Notch signaling, 269
stoichiometry of complex, 262
structure, 425
structure-function relationships, 265–266
subcellular sites of processing, 218–219
Gantenerumab, clinical trials, 445
GAP-43, cerebrospinal fluid biomarker studies, 100
GDS. See Geriatric Depression Scale; Global
Deterioration Scale
General Practitioner Assessment of Cognition
(GPCOG), 14
Geriatric Depression Scale (GDS), 14
Ginkgo biloba, Alzheimer disease treatment
studies, 482, 488
Global Deterioration Scale (GDS), 14
GLUT1, blood–brain barrier dysfunction in Alzheimer
disease, 409
Glycogen synthase kinase 3β (GSK3β)
apolipoprotein E receptor signaling, 285
inhibitor therapy, 461
GPCOG. See General Practitioner Assessment of
Cognition
Granovacuolar degeneration (GVD), 52
Growth hormone, Alzheimer disease treatment studies,
487
GSK3β. See Glycogen synthase kinase 3β
GSK933776A, clinical trials, 445
GVD. See Granovacuolar degeneration

H
Heat shock protein-70 (HSP70), Tau binding
with CHIP, 463
Heat shock protein-90 (HSP90), therapeutic
targeting, 463
Hippocampus, amyloid-β effects, 327, 329
Hirano bodies, 52
Histamine receptor, H3 antagonist therapy, 486
Homocysteine, levels in Alzheimer disease,
483–484
Homotaurine, Alzheimer disease treatment
studies, 484
HSP70. See Heat shock protein-70
HSP90. See Heat shock protein-90
Huperzine A, Alzheimer disease treatment
studies, 483
Hypertension, Alzheimer disease risk factor,
118–119

I
IDE. See Insulin-degrading enzyme
Idebenone, Alzheimer disease treatment studies, 488
Incidence. See Epidemiology, Alzheimer disease
Inflammation
Alzheimer disease studies
epidemiology, 346–347
gene polymorphisms in inflammation pathways,
345–346
prevention trials, 348
prospects for study, 348–439, 499
treatment trials, 347–348
arachidonic acid, 345
cellular mediators
astrocyte, 339–340
microglia, 336–339
neuron, 340–341
oligodendrocyte, 340
cerebrospinal fluid biomarkers for Alzheimer
disease, 100–101
complement system, 341–343
cyclooxygenase, 345
cytokines and chemokines, 343–344
Toll-like receptors, 344–345
Insulin, Alzheimer disease treatment studies,
486–487

© 2011 by Cold Spring Harbor Laboratory Press
Insulin-degrading enzyme (IDE), amyloid-β degradation, 395–396
Iron, amyloid-β interactions, 193

K
Ketasyn. See Axona

L
Language, Alzheimer disease deficits, 27
Late-onset Alzheimer disease (LOAD), genetics
AlzGene, 253
APOE, 252–253
genome-wide association studies, 253–255
overview, 124
Latrepirdine. See Dimebon
LDLR1
amyloid-β metabolism regulation, 290–291
amyloid precursor protein trafficking and processing regulation, 289–290
functional overview, 291–293
Leuprolide, Alzheimer disease treatment studies, 488
Lewy body. See Dementia with Lewy bodies
Lithium chloride, Tau phosphorylation inhibition therapy, 461, 464, 487
LOAD. See Late-onset Alzheimer disease
Logopenic progressive aphasia (LPA)
clinical presentation, 162
histopathology, 163
Long-term depression (LTD)
amyloid-β oligomer enhancement, 322–324
lysosomal network defects in induction, 376
LPA. See Logopenic progressive aphasia
LRP1
amyloid-β metabolism regulation, 290–291
amyloid precursor protein trafficking and processing regulation, 289–290
blood–brain barrier dysfunction in Alzheimer disease, 410–413
functional overview, 291–293
knockout mouse, 286
LTD. See Long-term depression
LY450139. See Semagacestat
LY451395, Alzheimer disease treatment studies, 486
LY2062430, clinical trials, 444–445
LY2811376, BACE inhibition, 432–434
Lyosomal network
Alzheimer disease role
genetic findings, 373–375
molecular pathology, 371–373
neuritic dystrophy, 375
neurodegeneration, 377
protein clearance failure and amyloidogenesis, 375–376
synaptic dysfunction, 376–377
tauopathy, 376
overview, 359–361, 369–371
therapeutic targeting, 377–378

M
Magnetic resonance imaging (MRI). See also Functional magnetic resonance imaging
diffusion tensor imaging, 80
initial assessment of dementia, 15
principles, 68–69
structural imaging in dementia, 15
advantages, 21
atrophy, 69–70
gross features, 45
limitations, 21
progression studies, 70–71
MAPT
early-onset familial Alzheimer disease mutations, 251
frontotemporal lobar degeneration mutations, 164, 169
Matrix metalloproteinases (MMPs), amyloid-β degradation, 395
MBP. See Myelin basic protein
MCI. See Mild cognitive impairment
Memantine, NMDA receptor antagonism and therapy, 480–481
MEOX2, expression in Alzheimer disease, 413–414
Methylene blue, Tau fibrillization inhibition, 466–467
Microglia, inflammation mediation, 336–339
Microglia, Alzheimer disease effects, 52
Mild Alzheimer disease
clinical presentation, 16
neuropathology, 54–55
Mild cognitive impairment (MCI)
diagnostic criteria, 19–20
neuropathology, 54–55
nonsteroidal anti-inflammatory drug prevention trials, 348
Mini-Mental Status Examination (MMSE), 14, 100, 429, 475
MK-0752, presenelin inhibition, 428
MMPs. See Matrix metalloproteinases
MMSE. See Mini-Mental Status Examination
MND. See Motor neuron disease
Moderate Alzheimer disease, clinical presentation, 16–17
Mortality, Alzheimer disease, 10, 16
Motor neuron disease (MND), frontotemporal dementia, 163, 170
MRI. See Magnetic resonance imaging
MSA6A/MSA4E, late-onset Alzheimer disease role, 254
Pathological criteria, Alzheimer disease diagnosis, 53–54
PAXIP1, early-onset familial Alzheimer disease mutations, 251
PCA. See Posterior cortical atrophy
PD. See Parkinson’s disease
PDE. See Phosphodiesterase
PEN2, early-onset familial Alzheimer disease mutations, 251
Peroxisome proliferator-activated receptor-γ (PPAR-γ), agonist therapy, 486–487, 489
PET. See Positron emission tomography
PF-03084014, presenelin inhibition, 428
PHE. See Paired helical filament
Phosphatidylinositol-binding clathrin assembly protein (PICALM), variants in Alzheimer disease, 123, 254
Phosphodiesterase (PDE), inhibitor therapy, 486
PiB. See Pittsburgh Compound-B
PICALM. See Phosphatidylinositol-binding clathrin assembly protein
Pin1, Tau interactions, 148
Pioglitazone, Alzheimer disease treatment studies, 486
Pittsburgh Compound-B (PiB), 76, 92, 444
Plasma biomarkers, Alzheimer disease, 102–103
Plasmin, amyloid-β degradation, 396
PNFA. See Progressive nonfluent aphasia
Positron emission tomography (PET) amyloid studies applications, 78–80 limitations, 80 principles, 77–78 fluorodeoxyglucose studies of Alzheimer disease biomarker utility, 76–77 hypometabolism pattern, 75–76 limitations, 77 overview, 15 principles, 74–75 Possible Alzheimer disease, diagnostic criteria, 11–13, 54
Posterior cortical atrophy (PCA), Alzheimer disease pathology, 29–30
PPA. See Primary progressive aphasia
PP2A. See Protein phosphatase 2A
PPAR-γ. See Peroxisome proliferator-activated receptor-γ
Pravastatin, Alzheimer disease treatment studies, 489
Prednisone, Alzheimer disease trials, 348

© 2011 by Cold Spring Harbor Laboratory Press
Index

Presenelins (Continued)
knockout mice, 307
Notch signaling, 269
processing, 261
structure, 260
structure-function relationships, 265–267
variants in Alzheimer disease, 123, 266, 268
Prevalence. See Epidemiology, Alzheimer disease
Primary progressive aphasia (PPA), Alzheimer disease
differential diagnosis, 32–33, 35
Probable Alzheimer disease, diagnostic criteria,
11–13, 54
Progressive nonfluent aphasia (PNFA)
clinical presentation, 161–162
histopathology, 163
Progressive supranuclear palsy (PSP)
clinical presentation, 162–163
histopathology, 163, 165
Proteasome. See Ubiquitin–proteasome system
Protein phosphatase 2A (PP2A), therapeutic targeting,
462
PPS. See Progressive supranuclear palsy

R
RAGE. See Receptor for advanced glycation end products
Receptor for advanced glycation end products (RAGE)
Alzheimer disease role, 344–345
blood–brain barrier dysfunction in Alzheimer
disease, 410
therapeutic targeting, 490
Reelin, apolipoprotein E receptor signaling, 285–287
Research driving forces, Alzheimer disease
competition of ideas and findings, 5–6
personal tragedy, 4
quest for scientific clarity, 3–4
societal crisis, 4–5
Resveratrol, Alzheimer disease treatment studies, 488,
491
Risk factors. See Epidemiology, Alzheimer disease
Rivastigmine, acetylcholinesterase inhibition, 476,
478–479
Rosiglitazone, Alzheimer disease treatment studies, 485, 488
S
SBT. See Short Blessed Test
scyllo-Inositol, amyloid-β aggregation inhibition, 437–438
SD. See Semantic dementia
Semagacestat (LY450139), presenelin inhibition,
269–270, 427
Semantic dementia (SD)
clinical presentation, 161
histopathology, 163
Semantic memory, Alzheimer disease deficits, 27–28
Serum response factor (SRF), expression in Alzheimer
disease, 413–414
Seven-Minute Screen, 14
Severe Alzheimer disease, clinical presentation, 16–17
Short Blessed Test (SBT), 14
SILK. See Stable Isotope Labeling Kinetics
Smoking, Alzheimer disease risk factor, 119–120
SORL1, variants in Alzheimer disease, 123–124
SorLA/LR1, amyloid-β production regulation, 212
Souvenaid, Alzheimer disease treatment studies, 485, 488
SRF. See Serum response factor
Stable Isotope Labeling Kinetics (SILK), cerebrospinal
fluid biomarker studies, 101–102
Statins, Alzheimer disease treatment studies, 487, 489
Stroke, Alzheimer disease risk factor, 118
Synapse, loss in Alzheimer disease, 53

T
TARDBP, frontotemporal lobar degeneration
mutations, 170
Tarenflurbil, presenelin inhibition, 270, 428, 430
Tau
acetylation, 418, 462
aggregation, 143
Alzheimer disease pathology, 140–143
BAP1tists versus TAUists, 5–6
binding partners, 145–149
cerebrospinal fluid biomarker studies
phosphorylation, 93–94
total protein, 92–93
degradation regulation, 369
distribution, 143–145
domains, 134–135
frontotemporal lobar degeneration histopathology,
163–167
FTDP-17 mutations, 457
gene. See MAPT
glycosylation, 142, 457, 462
history of study, 133–134
immunization therapy, 464–465
isoforms, 135, 456
lysosomal network defects in tauopathy, 376
microtubule binding, 455–456
microtubule interactions, 136–138, 141, 147
paired helical filament structure, 138–140
phosphorylation
inhibitors, 460–463
overview, 141–142
regulation by apolipoprotein E receptor, 286
proteolysis, 142
structure, 135–136
ubiquitination, 363–364
TDP43
FTLD-TDP, 167–168, 170

© 2011 by Cold Spring Harbor Laboratory Press
therapeutic targeting
  challenges, 457–458
  degradation enhancement, 463–465
  fibrillization inhibition, 466–467
  loss-of-function compensation, 459–460
  phosphorylation inhibitors, 460–463
  strategies, 458–459
Tetrodotoxin (TTX), amyloid precursor protein
  secretion effects, 220–222
Thioflavin T, amyloid-β aggregation studies, 435
TLRs. See Toll-like receptors
Toll-like receptors (TLRs), inflammation mediation,
  344–345
Tramiparote, amyloid-β aggregation inhibition,
  436–437
Traumatic brain injury, Alzheimer disease risk factor,
  120
TTX. See Tetrodotoxin

U
Ubiquitin–proteasome system
  Alzheimer disease role, 367–369
  amyloid-β degradation, 398
  FTLD-UPS, 168
  neurofibrillary tangle ubiquitination, 365–366
  overview, 359–361
  paired helical filament ubiquitin, 361–363
  Tau ubiquitination, 363–364
  ubiquitination steps, 366

V
VaD. See Vascular dementia
Valproic acid, Alzheimer disease treatment studies, 487
Vascular dementia (VaD), Alzheimer disease differential
diagnosis, 17–18, 33–34, 36
VCP, frontotemporal lobar degeneration mutations,
  170–171
Visinin-like protein-1, cerebrospinal fluid biomarker
  studies, 100
Visuospatial ability, Alzheimer disease deficits, 29–30
Vitamin B6, Alzheimer disease treatment studies, 484
Vitamin D, Alzheimer disease protection, 121
Vitamin E, Alzheimer disease treatment studies, 484, 488

W
Working memory, Alzheimer disease deficits, 28

X
Xaliproden, Alzheimer disease treatment studies, 488

Z
Zinc, amyloid-β interactions, 193